What is Neurotrack?
Neurotrack operates at the intersection of neurotechnology and digital health, providing a sophisticated platform designed to strengthen brain health. By leveraging remote cognitive testing, the company empowers individuals to take control of their neurological well-being. Their market position is defined by a commitment to clinical rigor and user-centric design, positioning them as a critical player in the preventative healthcare landscape. The company's ability to attract high-profile venture capital firms highlights the scalability of their digital-first approach to complex medical challenges.
How much funding has Neurotrack raised?
Neurotrack has raised a total of $47.6M across 5 funding rounds:
Series A
$2M
Debt
$1M
Private Equity
$9.9M
Series B
$13.7M
Series C
$21M
Series A (2013): $2M with participation from The Social+Capital Partnership and Founders Fund
Debt (2014): $1M, investors not publicly disclosed
Private Equity (2015): $9.9M supported by Khosla Ventures, Founders Fund, iSeed Ventures, AME Cloud Ventures, and Social Capital
Series B (2018): $13.7M featuring Marc Benioff, Khosla Ventures, Social Capital, Sozo Ventures, AME Cloud, Founders Fund, and Rethink Impact
Series C (2019): $21M backed by AME Cloud Partners, Sozo Ventures, Khosla Ventures, SOMPO Holdings, Dai-ichi Life, and Rethink Impact
Key Investors in Neurotrack
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies. The firm focuses on a broad range of areas including consumer, enterprise, AI, fintech, and health.
Founders Fund
Founders Fund invests in the world's most important and valuable companies across all geographies, sectors, and stages, pursuing a founder-friendly investment strategy.
Sozo Ventures
Sozo Ventures is an expansion-stage VC firm focused on connecting ambitious entrepreneurial teams with advanced global customers, with a specific focus on healthcare IT and emerging sectors.
What's next for Neurotrack?
Looking ahead, Neurotrack is well-positioned to leverage its recent capital injection to expand its clinical footprint and enhance its diagnostic algorithms. The strategic focus will likely shift toward deeper integration with healthcare providers and insurance networks, aiming to standardize remote cognitive monitoring as a routine preventative measure. As the company matures, the emphasis will remain on scaling its infrastructure to support a broader user base while maintaining the high data integrity required for neurological health assessments. Continued collaboration with global partners will be essential for navigating the regulatory and clinical complexities of the international healthtech market.
See full Neurotrack company page
